Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Bibb

Dermatology Myrtle Beach, SC Medical Doctor

NPI 1144267261 CMS profile 233318

917 Medical Circle, Myrtle Beach, SC 29572

Open in the dashboard

General payments

$4,449

243 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Bibb of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $4,449 across 243 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $70 2
2022 General $328 18
2021 General $1,273 74
2020 General $906 51
2019 General $1,873 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Bibb
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Robert Bibb were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Robert Bibb Dermatology median Middle half National median
2019 $1,873 $454 $129–$1,240 $163
2020 $906 $235 $81–$756 $114
2021 $1,273 $377 $108–$1,108 $132
2022 $328 $514 $143–$1,391 $149
2023 $70 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $624 36 payments
  2. Regeneron Healthcare Solutions, Inc. $459 26 payments
  3. Ortho Dermatologics, a division of Bausch Health US, LLC $443 19 payments
  4. Amgen Inc. $395 19 payments
  5. Pfizer Inc. $374 31 payments
  6. Novartis Pharmaceuticals Corporation $359 19 payments
  7. Janssen Biotech, Inc. $355 23 payments
  8. UCB, Inc. $308 17 payments
  9. Celgene Corporation $263 11 payments
  10. Sun Pharmaceutical Industries Inc. $232 15 payments
  11. Other $638 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,434 242 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2023
  1. SKYRIZI $478 29 payments
  2. DUPIXENT $443 25 payments
  3. TREMFYA $420 22 payments
  4. EUCRISA $359 30 payments
  5. HUMIRA $309 20 payments
  6. Cimzia $308 17 payments
  7. Otezla Inflammation $297 14 payments
  8. Otezla Dermatology $263 11 payments
  9. SILIQ $217 10 payments
  10. ILUMYA $213 14 payments
  11. Other $1,671 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

243 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record